Dr. William F. Rigby, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
NH license 6717
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Hitchcock Memorial Hospital Lebanon, NH
- Alice Peck Day Memorial Hospital Lebanon, NH
- New London Hospital New London, NH
Medical groups
- Dartmouth-Hitchcock Clinic (1,472 clinicians)
- Mary Hitchcock Memorial Hospital (1,280 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 215
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 74 | 53 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| Established patient office or other outpatient visit, 30-39 minutes | 29 | 28 |
| New patient office or other outpatient visit, 30-44 minutes | 20 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Lebanon, NH | 142 |
| Methotrexate (methotrexate sodium) Other prescribers in Lebanon, NH | 68 |
| Allopurinol Other prescribers in Lebanon, NH | 44 |
| Hydroxychloroquine Sulfate Other prescribers in Lebanon, NH | 43 |
| Celecoxib Other prescribers in Lebanon, NH | 26 |
| Omeprazole Other prescribers in Lebanon, NH | 20 |
| Ibuprofen Other prescribers in Lebanon, NH | 17 |
| Humira Pen (adalimumab) Other prescribers in Lebanon, NH | 17 |
| Enbrel (etanercept) Other prescribers in Lebanon, NH | 15 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Lebanon, NH | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $209 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $108 |
|---|---|
| AbbVie Inc. | $101 |
| Food and Beverage | $209 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 3 companies. The companies reported $518,313 in research payments for these studies, mostly to the institutions running them.
- A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR)
Novartis Pharmaceuticals Corporation - A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocortico…
Novartis Pharmaceuticals Corporation - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. · Active, not recruiting · NCT03671148 - A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT03915964 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
AbbVie Inc. · Completed · NCT03104400 - M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.